|
KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal …
The Herald | HeraldOnline.com KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered™ monoclonal antibody, in subjects with severe asthma … |
View full post on asthma – Google News